Although CPT-2 mRNA is a candidate IMP2 client, CPT-2 polypeptide abundance in the liver is not altered by IMP2 deficiency in the liver (Fig. 1F, bottom panel) or in AML cells (Fig. 3A, bottom panel), nor were there differences in CPT2 mRNA abundance, t1⁄2, or polysomal abundance (Fig. 3, A–C) in IMP2 CRISPR AML12 cells. The gene discussed is IGF2BP2; the disease is acute myeloid leukemia.